L-kynurenine

Metabolism and mechanism of neuroprotection

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

L-kynurenine is an intermediate in the pathway of the metabolism of L-tryptophan to nicotinic acid. L-kynurenine is formed in the mammalian brain (40%) and is taken up from the periphery (60%), indicating that it can be transported across the BBB. It was discovered some 30 years ago that compounds in the kynurenine family have neuroactive properties. L-kynurenine, the central agent of this pathway, can be converted into two other important compounds: the neuroprotective kynurenic acid and the neurotoxic quinolinic acid. Kynurenines have been shown to be involved in many diverse physiological and pathological processes. There are a number of neurodegenerative disorders whose pathogenesis has been demonstrated to involve multiple imbalances of the kynurenine pathway metabolism. This review summarizes the main steps of the kynurenine pathway under normal conditions, discusses the metabolic disturbances and changes in this pathway in certain neurodegenerative disorders, and finally introduces the therapeutic possibilities with kynurenines.

Original languageEnglish
Pages (from-to)169-188
Number of pages20
JournalFuture Neurology
Volume3
Issue number2
DOIs
Publication statusPublished - Mar 2008

Fingerprint

Kynurenine
Neurodegenerative Diseases
Physiological Phenomena
Kynurenic Acid
Quinolinic Acid
Neuroprotection
Niacin
Pathologic Processes
Tryptophan
Brain

Keywords

  • Kynurenic acid
  • Kynurenine metabolism
  • L-kynurenine
  • Neurodegenerative disorders
  • Neuroprotection

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

L-kynurenine : Metabolism and mechanism of neuroprotection. / Robotka, H.; Toldi, J.; Vécsei, L.

In: Future Neurology, Vol. 3, No. 2, 03.2008, p. 169-188.

Research output: Contribution to journalArticle

@article{4eb324d7245e4c409e88b710f4b08523,
title = "L-kynurenine: Metabolism and mechanism of neuroprotection",
abstract = "L-kynurenine is an intermediate in the pathway of the metabolism of L-tryptophan to nicotinic acid. L-kynurenine is formed in the mammalian brain (40{\%}) and is taken up from the periphery (60{\%}), indicating that it can be transported across the BBB. It was discovered some 30 years ago that compounds in the kynurenine family have neuroactive properties. L-kynurenine, the central agent of this pathway, can be converted into two other important compounds: the neuroprotective kynurenic acid and the neurotoxic quinolinic acid. Kynurenines have been shown to be involved in many diverse physiological and pathological processes. There are a number of neurodegenerative disorders whose pathogenesis has been demonstrated to involve multiple imbalances of the kynurenine pathway metabolism. This review summarizes the main steps of the kynurenine pathway under normal conditions, discusses the metabolic disturbances and changes in this pathway in certain neurodegenerative disorders, and finally introduces the therapeutic possibilities with kynurenines.",
keywords = "Kynurenic acid, Kynurenine metabolism, L-kynurenine, Neurodegenerative disorders, Neuroprotection",
author = "H. Robotka and J. Toldi and L. V{\'e}csei",
year = "2008",
month = "3",
doi = "10.2217/14796708.3.2.169",
language = "English",
volume = "3",
pages = "169--188",
journal = "Future Neurology",
issn = "1479-6708",
publisher = "Future Medicine Ltd.",
number = "2",

}

TY - JOUR

T1 - L-kynurenine

T2 - Metabolism and mechanism of neuroprotection

AU - Robotka, H.

AU - Toldi, J.

AU - Vécsei, L.

PY - 2008/3

Y1 - 2008/3

N2 - L-kynurenine is an intermediate in the pathway of the metabolism of L-tryptophan to nicotinic acid. L-kynurenine is formed in the mammalian brain (40%) and is taken up from the periphery (60%), indicating that it can be transported across the BBB. It was discovered some 30 years ago that compounds in the kynurenine family have neuroactive properties. L-kynurenine, the central agent of this pathway, can be converted into two other important compounds: the neuroprotective kynurenic acid and the neurotoxic quinolinic acid. Kynurenines have been shown to be involved in many diverse physiological and pathological processes. There are a number of neurodegenerative disorders whose pathogenesis has been demonstrated to involve multiple imbalances of the kynurenine pathway metabolism. This review summarizes the main steps of the kynurenine pathway under normal conditions, discusses the metabolic disturbances and changes in this pathway in certain neurodegenerative disorders, and finally introduces the therapeutic possibilities with kynurenines.

AB - L-kynurenine is an intermediate in the pathway of the metabolism of L-tryptophan to nicotinic acid. L-kynurenine is formed in the mammalian brain (40%) and is taken up from the periphery (60%), indicating that it can be transported across the BBB. It was discovered some 30 years ago that compounds in the kynurenine family have neuroactive properties. L-kynurenine, the central agent of this pathway, can be converted into two other important compounds: the neuroprotective kynurenic acid and the neurotoxic quinolinic acid. Kynurenines have been shown to be involved in many diverse physiological and pathological processes. There are a number of neurodegenerative disorders whose pathogenesis has been demonstrated to involve multiple imbalances of the kynurenine pathway metabolism. This review summarizes the main steps of the kynurenine pathway under normal conditions, discusses the metabolic disturbances and changes in this pathway in certain neurodegenerative disorders, and finally introduces the therapeutic possibilities with kynurenines.

KW - Kynurenic acid

KW - Kynurenine metabolism

KW - L-kynurenine

KW - Neurodegenerative disorders

KW - Neuroprotection

UR - http://www.scopus.com/inward/record.url?scp=40749131240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40749131240&partnerID=8YFLogxK

U2 - 10.2217/14796708.3.2.169

DO - 10.2217/14796708.3.2.169

M3 - Article

VL - 3

SP - 169

EP - 188

JO - Future Neurology

JF - Future Neurology

SN - 1479-6708

IS - 2

ER -